Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q05516
UPID:
ZBT16_HUMAN
Alternative names:
Promyelocytic leukemia zinc finger protein; Zinc finger protein 145; Zinc finger protein PLZF
Alternative UPACC:
Q05516; Q8TAL4
Background:
Zinc finger and BTB domain-containing protein 16, also known as Promyelocytic leukemia zinc finger protein, plays a crucial role in transcriptional repression, myeloid maturation, and tissue differentiation. It functions as a probable substrate-recognition component of an E3 ubiquitin-protein ligase complex, facilitating the ubiquitination and proteasomal degradation of target proteins.
Therapeutic significance:
The protein is implicated in Skeletal defects, genital hypoplasia, and impaired intellectual development, a disorder marked by intellectual disability and craniofacial dysmorphism. Understanding the role of Zinc finger and BTB domain-containing protein 16 could open doors to potential therapeutic strategies.